Search Result

Results for "

glucose oxidation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLUT (4) Akt (2) AMPK (4) Apoptosis (2) Bacterial (3) Biochemical Assay Reagents (3) Claudin (1) Disulfidptosis (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (15) ERK (2) Ferroptosis (1) FOXO (1) Glycosidase (1) HSP (1) IKK (1) Insulin Receptor (1) Interleukin Related (2) Isotope-Labeled Compounds (1) Keap1-Nrf2 (2) Liposome (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (6) Na+/K+ ATPase (1) NADPH Oxidase (1) NF-κB (4) NO Synthase (4) Oxidative Phosphorylation (1) PDHK (1) PDI (3) PGC-1α (1) PPAR (4) Reactive Oxygen Species (ROS) (5) Reference Standards (5) SOD (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) TRP Channel (1) VDAC (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (9) Endocrinology (2) Infection (6) Inflammation/Immunology (13) Metabolic Disease (38) Neurological Disease (6)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Glucose-6-Phosphate Isomerase (GPI) GLUT SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N8522

9,10-Dihydroxystearic acid	Others	Metabolic Disease
9,10-Dihydroxystearic acid is an oxidation product of oleic acid. 9,10-Dihydroxystearic acid can improve glucose tolerance and insulin sensitivity in KKAy mice .

HY-139577

Ninerafaxstat IMB-1018972; IMB-101	Mitochondrial Metabolism	Cardiovascular Disease Metabolic Disease
Ninerafaxstat (IMB-1018972) is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat can be used for research on cardiovascular diseases .

HY-139577A

Ninerafaxstat trihydrochloride MB-1018972 trihydrochloride; IMB-101 trihydrochloride	Mitochondrial Metabolism	Cardiovascular Disease Metabolic Disease
Ninerafaxstat trihydrochloride (IMB-1018972 trihydrochloride) is the trihydrochloride salt form of Ninerafaxstat (HY-139577). Ninerafaxstat trihydrochloride is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat trihydrochloride competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat trihydrochloride can be used for research on cardiovascular diseases .

HY-A0231

Glymidine sodium Gondafon; Glycodiazine	Insulin Receptor	Metabolic Disease
Glymidine sodium is an oral active antidiabetic. Glymidine sodium is the inhibitor of hepatic lipolysis. Glymidine sodium inhibits the glucose formation and supresses the elevated pyruvate oxidation which results from the inhibition of endogenous lipid mobilization .

HY-Y0624

4-Pentenoic acid	Endogenous Metabolite Mitochondrial Metabolism	Metabolic Disease
4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization .

HY-N9429

6-Deoxy-D-glucose	Others	Metabolic Disease
6-Deoxy-D-glucose is an inhibitor of glucose oxidation. 6-Deoxy-D-glucose is a structural homomorph of D-glucose, and can be used for study of D-glucose transport .

HY-17538A

ZLN005 hydrochloride	PGC-1α	Metabolic Disease
ZLN005 (hydrochloride) is a peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1α) activator. ZLN005 (hydrochloride) can stimulate the expression of PGC-1α and downstream genes in skeletal muscle cells, improve glucose utilization and fatty acid oxidation. ZLN005 (hydrochloride) can increase the transcription of PGC-1α and downstream genes in skeletal muscle of diabetic db/db mice, increase fat oxidation and improve glucose tolerance, pyruvate tolerance and insulin sensitivity .

HY-N3426

Kazinol B	NO Synthase Akt AMPK	Metabolic Disease
Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of *nitric oxide* (NO)** production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research .

HY-N2628

Erigeroside	Others	Metabolic Disease
Erigeroside is as a derivatives of -glucose extracted from Satureja khuzistanica Jamzad. Erigeroside has good ability of anti-oxidation and scavenging oxidation free radical .

HY-114509

Anilazine	Bacterial	Infection Metabolic Disease
Anilazine is a fungicide and inhibit the growth of Rhizobium sp. and E. coli. Anilazine inhibits glucose oxidation and succinate oxidation and also inhibits in vitro succinic dehydrogenase activity .

HY-125863

Glucose-6-phosphate dehydrogenase, Microorganism G6PD	Endogenous Metabolite	Metabolic Disease Cancer
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

HY-125863B

Glucose 6-phosphate dehydrogenase (yeast, recombinant) G6PD (yeast, recombinant)	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Glucose 6-phosphate dehydrogenase (yeast, recombinant) is the rate-limiting enzyme of the pentose phosphate pathway and a major source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, and cytochrome P450 systems. Glucose 6-phosphate dehydrogenase helps cells resist oxidative stress and regulates metabolic rates. It holds potential for research in fields such as diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

HY-P3186

Glucose dehydrogenase, recombinant Microorganisms	Endogenous Metabolite	Metabolic Disease
Glucose dehydrogenase, recombinant Microorganisms is a FDA-dependent oxidoreductase. Glucose dehydrogenase (GDH) catalyzes the oxidation of β-D-glucose to β-D-glucono-1,5-lactone with simultaneous reduction of the cofactor NADP ⁺ to NADPH or, to a lesser extent, NAD ⁺ to NADH. Glucose dehydrogenase (GDH) accepts both NAD ⁺ and NADP ⁺ as cofactors and can be used for the regeneration of NADH and NADPH .

HY-W587877

Triundecanoin	Biochemical Assay Reagents	Others
Triundecanoin is a triacylglycerol. Triundecanoin maintain the glucose supplement during fasting through β-oxidation and acetyl-CoA production in rat models .

HY-130319A

9-HEPE	PPAR	Cardiovascular Disease Metabolic Disease
9-HEPE, a oxidation product of Eicosapentaenoic acid, is a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. 9-HEPE induces fatty acid oxidation, adipogenesis, and glucose uptake via activation of PPARs in vivo .

HY-123962

G6PD activator AG1 5+ Cited Publications	NADPH Oxidase	Metabolic Disease
G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) agonist with an EC50 of 3 μM. G6PD is an oxidoreductase that catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconolactone and the simultaneous reduction of NAD phosphate (NADP) to reduced NADP (NADPH). G6PD activator AG1 can reduce hemolysis of human erythrocytes .

HY-W007972R

Methyl 3-methoxyacrylate (Standard) 3-Methoxyacrylic Acid Methyl Ester (Standard)	Reference Standards Others	Others
Anilazine (Standard) is the analytical standard of Anilazine. This product is intended for research and analytical applications. Anilazine is a fungicide and inhibit the growth of Rhizobium sp. and E. coli. Anilazine inhibits glucose oxidation and succinate oxidation and also inhibits in vitro succinic dehydrogenase activity .

HY-114509R

Anilazine (Standard)	Reference Standards Bacterial	Infection Metabolic Disease
Anilazine (Standard) is the analytical standard of Anilazine. This product is intended for research and analytical applications. Anilazine is a fungicide and inhibit the growth of Rhizobium sp. and E. coli. Anilazine inhibits glucose oxidation and succinate oxidation and also inhibits in vitro succinic dehydrogenase activity .

HY-P3186A

NAD-dependent Glucose dehydrogenase GDH-NAD	Endogenous Metabolite	Metabolic Disease
NAD-dependent Glucose dehydrogenase (GDH-NAD) ((EC 1.1.1.47)) is a NAD-dependent oxidoreductase. Glucose dehydrogenase (GDH) catalyzes the oxidation of β-D-glucose to β-D-glucono-1,5-lactone with simultaneous reduction of the cofactor NADP ⁺ to NADPH or, to a lesser extent, NAD ⁺ to NADH. Glucose dehydrogenase (GDH) accepts both NAD ⁺ and NADP ⁺ as cofactors and can be used for the regeneration of NADH and NADPH .

HY-P1184

HNGF6A	Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Metabolic Disease
HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo .

HY-Y0624R

4-Pentenoic acid (Standard)	Reference Standards Endogenous Metabolite Mitochondrial Metabolism	Metabolic Disease
4-Pentenoic acid (Standard) is the analytical standard of 4-Pentenoic acid (HY-Y0624). This product is intended for research and analytical applications. 4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization.

HY-P1184A

HNGF6A TFA	Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Metabolic Disease
HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo .

HY-126718

Methylenecyclopropylpyruvate Ketohypoglycin	Mitochondrial Metabolism	Metabolic Disease
Methylenecyclopropylpyruvate (Ketohypoglycin) is an inhibitor for gluconeogenesis. Methylenecyclopropylpyruvate inhibits ketogenesis and affects the fatty acids metabolism. Methylenecyclopropylpyruvate may interfere with the mitochondrial β-oxidation pathway, affects the contents and composition of coenzyme A, and affects the glucose homeostasis .

HY-139172

MD001	PPAR	Metabolic Disease
MD001 is a PPARα/γ dual agonist and can increase the transcriptional activity of PPARα and PPARγ. MD001 enhances the expression of genes related to β-oxidation and fatty acid and glucose uptake .

HY-W012530

Phenylpyruvic acid	Endogenous Metabolite PDI	Infection Metabolic Disease
Phenylpyruvic acid is a precursor of the antifungal compound phenyllactic acid. Phenylpyruvic acid can improve the antifungal activity of eight lactic acid bacterial strains through the addition into a dedined growth medium. Phenylpyruvic acid demonstrates improved inhibitory activity against fungal bread contaminants Aspergillus niger and Penicillium roqueforti. Phenylpyruvic acid affects enzyme activity of the pentose phosphate pathway involved in the oxidative phase in rat brain homogenates. Phenylpyruvic acid can reduce glucose-6-phosphate dehydrogenase activity .

HY-N15691

Tadehaginoside	Keap1-Nrf2 NF-κB	Metabolic Disease Inflammation/Immunology
Tadehaginoside, a phenylpropanoid glycoside, is a regulator of lipogenesis and glucose consumption. Tadehaginoside has antioxygenic property. Tadehaginoside mediates liver protection against oxidative stress injury and inflammation by regulating Nrf2 and NF-κB signaling pathways in hepatocytes. Tadehaginoside can be used for the study of obesity and diabetes .

HY-E70020

UDP-Glc dehydrogenase (UGDH)	Others	Others
UDP-Glc dehydrogenase (UGDH) catalyzes is a NAD+-dependent enzyme that catalyzes the two-fold oxidation of UDP-glucose (UDP-Glc) to produce UDP-glucuronic acid. UDP-Glc dehydrogenase (UGDH) is a key enzyme in the nucleotide-sugar interconversion pathway necessary for biosynthesis of many cell-wall polysaccharides .

HY-W229874

EN106	E1/E2/E3 Enzyme NF-κB Reactive Oxygen Species (ROS) SOD	Cancer
EN106 is a potent inhibitor of FEMIB. EN106 is a cysteine-reactive covalent ligand. EN106 disrupts recognition of the key reductive stress substrate of FEM1B, FNIP1. EN106 reduces oxidative stress and rescues high glucose-induced impaired angiogenesis in HUVECs .

HY-W012530R

Phenylpyruvic acid (Standard)	Reference Standards Endogenous Metabolite PDI	Infection Metabolic Disease
Phenylpyruvic acid (Standard) is the analytical standard of Phenylpyruvic acid. This product is intended for research and analytical applications. Phenylpyruvic acid is a precursor of the antifungal compound phenyllactic acid. Phenylpyruvic acid can improve the antifungal activity of eight lactic acid bacterial strains through the addition into a dedined growth medium. Phenylpyruvic acid demonstrates improved inhibitory activity against fungal bread contaminants Aspergillus niger and Penicillium roqueforti. Phenylpyruvic acid affects enzyme activity of the pentose phosphate pathway involved in the oxidative phase in rat brain homogenates. Phenylpyruvic acid can reduce glucose-6-phosphate dehydrogenase activity .

HY-W016203

Phenylpyruvic acid sodium Sodium phenylpyruvate	Endogenous Metabolite PDI	Infection Metabolic Disease
Phenylpyruvic acid sodium is a endogenous metabolite that participates in the synthesis of 3-phenyllactic acid (PLA) by lactate dehydrogenase. Phenylpyruvic acid is a precursor of the antifungal compound phenyllactic acid. Phenylpyruvic acid can improve the antifungal activity of eight lactic acid bacterial strains through the addition into a dedined growth medium. Phenylpyruvic acid demonstrates improved inhibitory activity against fungal bread contaminants Aspergillus niger and Penicillium roqueforti. Phenylpyruvic acid affects enzyme activity of the pentose phosphate pathway involved in the oxidative phase in rat brain homogenates. Phenylpyruvic acid can reduce glucose-6-phosphate dehydrogenase activity .

HY-129297

CMPF	Endogenous Metabolite	Metabolic Disease
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .

HY-149405

Squalene synthase-IN-1	Others	Metabolic Disease
Squalene synthase-IN-1 (compound 1) is a potent antihyperlipidemic agent acting through Squalene Synthase inhibition. Squalene synthase-IN-1 exhibits an outstanding antioxidant and anti-inflammatory activity. Squalene synthase-IN-1 displays a significant reduction not only of glucose but also of oxidative stress levels, while it did not cause any toxicity .

HY-115507A

(Z)-NMac1	Oxidative Phosphorylation Mitochondrial Metabolism	Cancer
(Z)-NMac1 is an Nm23-H1 activator found in Zingiber cassumunar Roxb. (Z)-NMac1 has dual anti-metastatic and anti-proliferative biological activities. (Z)-NMac1 selectively inhibits cancer cell proliferation under glucose starvation conditions by inhibiting mitochondrial complex I activity, leading to ATP depletion and mitochondrial dysfunction. (Z)-NMac1 can be used to study tumors with high oxidative phosphorylation, especially in the glucose-restricted tumor microenvironment .

HY-N15691A

(E)-Tadehaginoside	Keap1-Nrf2 NF-κB	Metabolic Disease Inflammation/Immunology
(E)-Tadehaginoside is the E-isomer of Tadehaginoside (HY-N15691). Tadehaginoside, a phenylpropanoid glycoside, is a regulator of lipogenesis and glucose consumption. Tadehaginoside has antioxygenic property. Tadehaginoside mediates liver protection against oxidative stress injury and inflammation by regulating Nrf2 and NF-κB signaling pathways in hepatocytes. Tadehaginoside can be used for the study of obesity and diabetes .

HY-170313

GLUT-1-IN-4	GLUT Apoptosis Reactive Oxygen Species (ROS)	Cancer
GLUT-1-IN-4 (Compound 13) is the p53 protein-dependent inhibitor for *GLUT-1 glucose* transporter. GLUT-1-IN-4 inhibits the proliferation of multiple cancer cells with IC₅₀** in submicromolar levels. GLUT-1-IN-4 arrests the cell cycle, stimulates oxidative stress, and induces apoptosis .

HY-126415

Magnesium Lithospermate B	Na+/K+ ATPase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Magnesium Lithospermate B, is a derivative of caffeic acid tetramer and an inhibitor of Na+/K+ ATPase, which can be extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroin?ammation and attenuates neurodegeneration .

HY-145963

DRB18	GLUT	Cancer
DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity .

HY-W127499

1,2-Dierucoyl-sn-glycero-3-phosphocholine DEPC; L-Dierucoyl lecithin; Dierucoyllecithin	Liposome	Others
1,2-Dierucoyl-sn-glycero-3-phosphocholine (DEPC) is the composition of liposome membrane. 1,2-Dierucoyl-sn-glycero-3-phosphocholine is used for the preparation of liposomes and studying the properties of lipid bilayers. The GO (glucose oxidase) in the 1,2-Dierucoyl-sn-glycero-3-phosphocholine liposome shows the high activity .

HY-B1092A

Gluconate sodium D-Gluconic acid sodium salt; Sodium D-gluconate; D-Gluconate sodium salt	Endogenous Metabolite NO Synthase Interleukin Related ERK	Cardiovascular Disease Inflammation/Immunology Cancer
Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .

HY-B1092AR

Gluconate sodium (Standard) D-Gluconic acid sodium salt (Standard); Sodium D-gluconate (Standard); D-Gluconate sodium salt (Standard)	Reference Standards Endogenous Metabolite	Others Cancer
Gluconate (sodium) (Standard) is the analytical standard of Gluconate (sodium). This product is intended for research and analytical applications. Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .

HY-B0481

Miglitol 1 Publications Verification BAY1099; BAY-m1099	Glycosidase AMPK Reactive Oxygen Species (ROS)	Metabolic Disease
Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets .

HY-159944

PPARγ agonist 14	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC₅₀=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .

HY-108458

SB 452533	TRP Channel	Inflammation/Immunology
SB 452533 is a potent and selective TRPV1 antagonist with the pK_b of 7.8 .

HY-168049

ZLY06	PPAR Akt	Metabolic Disease
ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC₅₀=341 nM; PPAR γ: EC₅₀=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .

HY-W768336

Gluconate-13C6 sodium D-Gluconic acid-¹³C₆ sodium; D-Gluconate-¹³C₆ sodium	Isotope-Labeled Compounds Interleukin Related ERK NO Synthase Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Cancer
Gluconate sodium- ¹³C₆ (D-Gluconic acid sodium salt- ¹³C₆) is the ¹³C-labeled Gluconate sodium (HY-B1092A). Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .

HY-134816

D-Glucan	Toll-like Receptor (TLR)	Metabolic Disease Inflammation/Immunology Cancer
D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism) .

HY-121744

PS10 3 Publications Verification	PDHK	Inflammation/Immunology
PS10 is a novel, potent and ATP-competitive pan-PDK inhibitor, inhibits all PDK isoforms with IC₅₀ of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (K_d= 239 nM) than for Hsp90 (K_d= 47 μM) . PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy .PDK: pyruvate dehydrogenase kinase

HY-W142618

D-Glucal	Biochemical Assay Reagents	Others
D-Glucal is an organic compound belonging to the family of aldoses, which are monosaccharides containing an aldehyde functional group. It has a six-carbon structure and is derived from glucose by oxidation of the primary alcohol group at carbon 1 to an aldehyde group. D-Glucal is a white crystalline solid that is soluble in water and has a sweet taste. It is an important intermediate in the chemical synthesis of a wide variety of compounds, including pharmaceuticals, agrochemicals, and natural products. D-Glucal can be converted into other carbohydrate derivatives such as glycosides, glycoconjugates and amino sugars. It also plays a role in the study of carbohydrate chemistry, where it is used as a chiral building block for the synthesis of complex structures.

HY-W145521

β-1,3-Glucan β Glucan	Biochemical Assay Reagents IKK NO Synthase Bacterial	Infection Inflammation/Immunology Cancer
β-1,3-Glucan (β Glucan) is an orally active polysaccharide composed of glucose polymers. β-1,3-Glucan increase the activity of IKKβ kinase, enhances the production of nitric oxide. β-1,3-Glucan improves resistance to *Vibrio harveyi* infection. β-1,3-Glucan enhances immune response, promotes blood pressure recovery, reduces lung, kidney and liver damage, inhibits the growth of syngeneic tumors .

HY-15763

Erastin Maximum Cited Publications 567 Publications Verification	VDAC Ferroptosis Disulfidptosis	Cancer
Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .

Cat. No.	Product Name

HY-L092

Glucose Metabolism Compound Library

1,327 compounds

Glucose homeostasis is tightly regulated to meet the energy requirements of the vital organs and maintain an individual’s health. Glucose metabolism includes glycolysis, tricarboxylic acid cycle, pentose phosphate pathway, oxidative phosphorylation and other metabolic pathways. Glucose is the major carbon source that provides the main energy for life. Glucose metabolism dysregulation is also implicated in many diseases such as diabetes, heart disease, neurodegenerative diseases and even cancer.

MCE offers a unique collection of 1,327 compounds related to glucose metabolism, which target glucose metabolism related targets, such as GLUT, Hexokinase, Pyruvate Kinase, IDH, etc. MCE glucose metabolism library is a powerful tool for studying glucose metabolism and drug discovery of diseases related to glucose metabolism.

HY-L045

Oxygen Sensing Compound Library

3,261 compounds

Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.

HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.

MCE offers a unique collection of 3,261 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Cat. No.	Product Name	Type

HY-W127499

1,2-Dierucoyl-sn-glycero-3-phosphocholine DEPC; L-Dierucoyl lecithin; Dierucoyllecithin	Drug Delivery
1,2-Dierucoyl-sn-glycero-3-phosphocholine (DEPC) is the composition of liposome membrane. 1,2-Dierucoyl-sn-glycero-3-phosphocholine is used for the preparation of liposomes and studying the properties of lipid bilayers. The GO (glucose oxidase) in the 1,2-Dierucoyl-sn-glycero-3-phosphocholine liposome shows the high activity .

HY-134816

D-Glucan

Carbohydrates

D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism) .

HY-W142618

D-Glucal

Carbohydrates

D-Glucal is an organic compound belonging to the family of aldoses, which are monosaccharides containing an aldehyde functional group. It has a six-carbon structure and is derived from glucose by oxidation of the primary alcohol group at carbon 1 to an aldehyde group. D-Glucal is a white crystalline solid that is soluble in water and has a sweet taste. It is an important intermediate in the chemical synthesis of a wide variety of compounds, including pharmaceuticals, agrochemicals, and natural products. D-Glucal can be converted into other carbohydrate derivatives such as glycosides, glycoconjugates and amino sugars. It also plays a role in the study of carbohydrate chemistry, where it is used as a chiral building block for the synthesis of complex structures.

HY-W145521

β-1,3-Glucan

β Glucan

Carbohydrates

β-1,3-Glucan (β Glucan) is an orally active polysaccharide composed of glucose polymers. β-1,3-Glucan increase the activity of IKKβ kinase, enhances the production of nitric oxide. β-1,3-Glucan improves resistance to Vibrio harveyi infection. β-1,3-Glucan enhances immune response, promotes blood pressure recovery, reduces lung, kidney and liver damage, inhibits the growth of syngeneic tumors .

Cat. No.	Product Name	Target	Research Area

HY-P2048

MOTS-c (human)	Apoptosis GLUT AMPK	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
MOTS-c (human) is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .

HY-P2048A

MOTS-c(human) acetate	AMPK GLUT	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
MOTS-c (human) acetate is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) acetate inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) acetate has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .

HY-P1184

HNGF6A	Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Metabolic Disease
HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo .

HY-P1184A

HNGF6A TFA	Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Metabolic Disease
HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8522

9,10-Dihydroxystearic acid	Classification of Application Fields Ricinus communis L. Ketones, Aldehydes, Acids Source classification Metabolic Disease Euphorbiaceae Plants Disease Research Fields	Others
9,10-Dihydroxystearic acid is an oxidation product of oleic acid. 9,10-Dihydroxystearic acid can improve glucose tolerance and insulin sensitivity in KKAy mice .

HY-Y0624

4-Pentenoic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Mitochondrial Metabolism
4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization .

HY-125863

Glucose-6-phosphate dehydrogenase, Microorganism G6PD	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

HY-W012530

Phenylpyruvic acid	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Other Diseases Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields	Endogenous Metabolite PDI
Phenylpyruvic acid is a precursor of the antifungal compound phenyllactic acid. Phenylpyruvic acid can improve the antifungal activity of eight lactic acid bacterial strains through the addition into a dedined growth medium. Phenylpyruvic acid demonstrates improved inhibitory activity against fungal bread contaminants Aspergillus niger and Penicillium roqueforti. Phenylpyruvic acid affects enzyme activity of the pentose phosphate pathway involved in the oxidative phase in rat brain homogenates. Phenylpyruvic acid can reduce glucose-6-phosphate dehydrogenase activity .

HY-N9429

6-Deoxy-D-glucose	Structural Classification Source classification Endogenous metabolite Saccharides Monosaccharides	Others
6-Deoxy-D-glucose is an inhibitor of glucose oxidation. 6-Deoxy-D-glucose is a structural homomorph of D-glucose, and can be used for study of D-glucose transport .

HY-N3426

Kazinol B	Structural Classification other families Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	NO Synthase Akt AMPK
Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of *nitric oxide* (NO)** production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research .

HY-N2628

Erigeroside	other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Plants Disease Research Fields	Others
Erigeroside is as a derivatives of -glucose extracted from Satureja khuzistanica Jamzad. Erigeroside has good ability of anti-oxidation and scavenging oxidation free radical .

HY-W007972R

Methyl 3-methoxyacrylate (Standard) 3-Methoxyacrylic Acid Methyl Ester (Standard)	Structural Classification Natural Products Microorganisms Source classification	Reference Standards Others
Anilazine (Standard) is the analytical standard of Anilazine. This product is intended for research and analytical applications. Anilazine is a fungicide and inhibit the growth of Rhizobium sp. and E. coli. Anilazine inhibits glucose oxidation and succinate oxidation and also inhibits in vitro succinic dehydrogenase activity .

HY-Y0624R

4-Pentenoic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite Mitochondrial Metabolism
4-Pentenoic acid (Standard) is the analytical standard of 4-Pentenoic acid (HY-Y0624). This product is intended for research and analytical applications. 4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization.

HY-N15691

Tadehaginoside	Structural Classification Labiatae Scutellaria salviifolia Benth. Source classification Phenols Polyphenols Plants	Keap1-Nrf2 NF-κB
Tadehaginoside, a phenylpropanoid glycoside, is a regulator of lipogenesis and glucose consumption. Tadehaginoside has antioxygenic property. Tadehaginoside mediates liver protection against oxidative stress injury and inflammation by regulating Nrf2 and NF-κB signaling pathways in hepatocytes. Tadehaginoside can be used for the study of obesity and diabetes .

HY-W012530R

Phenylpyruvic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite	Reference Standards Endogenous Metabolite PDI
Phenylpyruvic acid (Standard) is the analytical standard of Phenylpyruvic acid. This product is intended for research and analytical applications. Phenylpyruvic acid is a precursor of the antifungal compound phenyllactic acid. Phenylpyruvic acid can improve the antifungal activity of eight lactic acid bacterial strains through the addition into a dedined growth medium. Phenylpyruvic acid demonstrates improved inhibitory activity against fungal bread contaminants Aspergillus niger and Penicillium roqueforti. Phenylpyruvic acid affects enzyme activity of the pentose phosphate pathway involved in the oxidative phase in rat brain homogenates. Phenylpyruvic acid can reduce glucose-6-phosphate dehydrogenase activity .

HY-129297

CMPF	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .

HY-N15691A

(E)-Tadehaginoside	Structural Classification Leguminosae Source classification Phenols Polyphenols Tadehagi triquetrum (L.) Ohashi Plants	Keap1-Nrf2 NF-κB
(E)-Tadehaginoside is the E-isomer of Tadehaginoside (HY-N15691). Tadehaginoside, a phenylpropanoid glycoside, is a regulator of lipogenesis and glucose consumption. Tadehaginoside has antioxygenic property. Tadehaginoside mediates liver protection against oxidative stress injury and inflammation by regulating Nrf2 and NF-κB signaling pathways in hepatocytes. Tadehaginoside can be used for the study of obesity and diabetes .

HY-126415

Magnesium Lithospermate B	Cardiovascular Disease Structural Classification Neurological Disease Classification of Application Fields Simple Phenylpropanols Labiatae Samanea saman (Jacq.) Merr. Source classification Phenylpropanoids Plants Disease Research Fields	Na+/K+ ATPase
Magnesium Lithospermate B, is a derivative of caffeic acid tetramer and an inhibitor of Na+/K+ ATPase, which can be extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroin?ammation and attenuates neurodegeneration .

HY-B1092A

Gluconate sodium D-Gluconic acid sodium salt; Sodium D-gluconate; D-Gluconate sodium salt	Structural Classification other families Classification of Application Fields Anti-aging Source classification Other Diseases Plants Endogenous metabolite Disease Research Fields Saccharides Monosaccharides	Endogenous Metabolite NO Synthase Interleukin Related ERK
Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .

HY-B1092AR

Gluconate sodium (Standard) D-Gluconic acid sodium salt (Standard); Sodium D-gluconate (Standard); D-Gluconate sodium salt (Standard)	Structural Classification other families Source classification Plants Endogenous metabolite Saccharides Monosaccharides	Reference Standards Endogenous Metabolite
Gluconate (sodium) (Standard) is the analytical standard of Gluconate (sodium). This product is intended for research and analytical applications. Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .

HY-N2468

Xylobiose 1,4-β-D-Xylobiose; 1,4-D-Xylobiose	Structural Classification Zea mays L. Polysaccharides Classification of Application Fields Gramineae Source classification Other Diseases Plants Disease Research Fields Saccharides	TNF Receptor Claudin HSP
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .

HY-N3021

D-chiro-Inositol	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N7075

Inulin 2 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Polysaccharides Classification of Application Fields Source classification Metabolic Disease Plants Compositae Endogenous metabolite Disease Research Fields Saccharides Sophora tomentosa L.	Endogenous Metabolite
Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: ① Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; ② Enhancing the intestinal barrier function and reducing endotoxin translocation; ③ Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].

Cat. No.	Product Name	Chemical Structure

HY-W768336

Gluconate-13C6 sodium

Gluconate sodium- ¹³C₆ (D-Gluconic acid sodium salt- ¹³C₆) is the ¹³C-labeled Gluconate sodium (HY-B1092A). Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .

Cat. No.	Product Name		Classification

HY-W127499

1,2-Dierucoyl-sn-glycero-3-phosphocholine DEPC; L-Dierucoyl lecithin; Dierucoyllecithin		Phospholipids
1,2-Dierucoyl-sn-glycero-3-phosphocholine (DEPC) is the composition of liposome membrane. 1,2-Dierucoyl-sn-glycero-3-phosphocholine is used for the preparation of liposomes and studying the properties of lipid bilayers. The GO (glucose oxidase) in the 1,2-Dierucoyl-sn-glycero-3-phosphocholine liposome shows the high activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

glucose oxidation

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products